Skip to main content
. 2023 Nov 6;80(12):1317–1325. doi: 10.1001/jamaneurol.2023.3997

Figure 2. Future Risk of Confirmed Disability Worsening With Clinical Relapses (CDW-R) Based on Neurofilament Light Chain (NfL) z Score.

Figure 2.

In the Expression, Proteomics, Imaging, Clinical (EPIC) study (A) and Swiss Multiple Sclerosis Cohort (SMSC) (B), NfL z score less than or equal to 1 or greater than 1 was used as a time-varying covariate, correcting for age, sex, disease course (relapsing vs progressive multiple sclerosis [MS]), disease-modifying treatment (DMT) category (monoclonal antibodies, oral DMT, platform DMT, and untreated), recent relapse (within 90 days) at measurement visit, and Expanded Disability Status Scale at baseline. aHR indicates adjusted hazard ratio.